Mandatum Life Insurance Co Ltd Continues to Hold Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Mandatum Life Insurance Co Ltd held its position in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 42,466 shares of the biopharmaceutical company’s stock at the end of the second quarter. Mandatum Life Insurance Co Ltd’s holdings in Gilead Sciences were worth $3,006,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in GILD. Hall Laurie J Trustee increased its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the period. Cable Hill Partners LLC increased its position in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. increased its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Finally, Penserra Capital Management LLC increased its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the last quarter. Hedge funds and other institutional investors own 74.02% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ GILD) traded down 0.32% during trading on Friday, reaching $72.11. 6,052,601 shares of the company’s stock traded hands. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $82.10. The stock has a market cap of $94.17 billion, a price-to-earnings ratio of 7.83 and a beta of 1.21. The company’s 50 day moving average is $72.61 and its 200-day moving average is $68.83.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the previous year, the firm earned $3.08 EPS. The business’s quarterly revenue was down 8.2% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.88%. Gilead Sciences’s payout ratio is currently 22.58%.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/19/mandatum-life-insurance-co-ltd-maintains-stake-in-gilead-sciences-inc-nasdaqgild-updated-updated-updated.html.

Several brokerages have recently weighed in on GILD. Jefferies Group LLC reiterated a “hold” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 11th. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price target on the stock. in a research report on Tuesday, April 25th. Finally, BMO Capital Markets restated a “hold” rating and issued a $76.00 price target (up from $75.00) on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Eleven research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $80.31.

In related news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the completion of the transaction, the executive vice president now directly owns 137,488 shares in the company, valued at $10,174,112. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 206,666 shares of company stock worth $15,223,184. Insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit